|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
|
|
NOTIFICATION
OF LATE FILING
|
SEC.
FILE NUMBER
1-09731
|
||||||||
|
(Check
One): o Form
10-K and Form 10-KSB o
Form 20-F o
Form 11-K [
X ]
Form 10-Q and Form 10-QSB o
Form N-SAR
|
CUSIP
NUMBER
042698
30 8
|
||||||||
|
|
For
Period Ended: March 31, 2007
|
|
|||||||
|
|
o
Transition
Report on Form 10-K
|
|
|||||||
|
|
o
Transition
Report on Form 20-F
|
|
|||||||
|
|
o
Transition
Report on Form 11-K
|
|
|||||||
|
|
o
Transition
Report on Form 10-Q
|
|
|||||||
|
|
o
Transition
Report on Form N-SAR
|
|
|||||||
|
|
For
the Transition Period Ended:
|
|
|||||||
|
PART
I - REGISTRANT INFORMATION
Arrhythmia
Research Technology Inc.
Full
Name of Registrant
|
|
Not
applicable
Former
Name if Applicable
|
|
25
Sawyer Passway
Address
of Principal Executive Office (Street
and Number)
Fitchburg,
MA 01420
City,
State and Zip Code
|
|
x
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could
not
be eliminated without unreasonable effort or expense;
|
|
|
[
]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form
10-K,
Form 10-KSB, Form 20-F, 11-K or Form N-SAR, or portion thereof, will
be
filed on or before the fifteenth calendar day following the prescribed
due
date; or the subject quarterly report of transition report on Form
10-Q,
or portion thereof will be filed on or before the fifth calendar
day
following the prescribed due date; and
|
|
|
[
]
|
(c)
|
The
accountant's statement or other exhibit required by Rule 12b-25(c)
has
been attached if applicable.
|
|
|
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
|
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of
the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period
that
the registrant was required to file such report(s) been filed? If
answer
is no, identify report(s).
|
x
Yes o
No
|
|
(3)
|
Is
it anticipated that any significant change in results of operations
from
the corresponding period for the last fiscal year will be reflected
by the
earnings statements to be included in the subject report or portion
thereof?
|
x
Yes o
No
|
|
|
If
so, attach an explanation of the anticipated change, both narrative
and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made
* Arrhythmia
Research Technology, Inc. (the “Company”) (AMEX: HRT) and its wholly owned
subsidiary Micron Products, Inc. (“Micron”) reported total revenue of
$5,009,000 and net income of $234,000 for the quarter ended March
31, 2007
compared to total revenue of $4,269,000 and net income of $521,000
for the
same quarter of 2006. Net income per share for the three months ended
March 31, 2007 decreased to $ 0.09 per share from $ 0.20 per share
for the
same period in 2006.
Total
revenue increased by 17% in the quarter ending March 31, 2007 as
compared
to the same period in 2006. Revenue from Micron’s medical sensors and
snaps with silver surcharge decreased $510,000, while high volume
precision molded products and other miscellaneous sales increased
$90,000
in the quarter. More than half of the decrease in sensors and snaps
sales
was due to a precipitous drop in European sensor sales, primarily
due to
excessive customer inventory levels. The remaining decrease was due
to the
shift of a customer’s orders normally filled by Micron to a competitor due
to pricing differences. Revenue from Micron’s New England Molders (“NEM”)
division’s custom molded products increased $532,000, and Micron
Integrated Technology (“MIT”) division’s sales increased $419,000. The new
Leominster Tool division contributed $209,000 to the increase in
revenue
for the quarter.
|
|
|
By:
/s/ David A. Garrison
|
|